Your browser doesn't support javascript.
loading
Predicting dupilumab effectiveness with Type-2 biomarkers: A real-world study of severe asthma.
Mizumura, Kenji; Gon, Yasuhiro; Harada, Norihiro; Yamada, Shiho; Fukuda, Asami; Ozoe, Ryosuke; Maruoka, Shuichiro; Abe, Sumiko; Takahashi, Kazuhisa; Tanaka, Akihiko; Sagara, Hironori; Akamatsu, Taisuke; Shirai, Toshihiro; Masaki, Katsunori; Fukunaga, Koichi; Kobayashi, Konomi; Nagase, Hiroyuki; Miyahara, Nobuaki; Kanehiro, Arihiko; Kitamura, Noboru; Sugihara, Naruhiko; Kumasawa, Fumio; Terada-Hirashima, Junko; Hojo, Masayuki; Chibana, Kazuyuki; Tagaya, Etsuko.
Afiliación
  • Mizumura K; Division of Respiratory Medicine, Department of Internal Medicine, Nihon University School of Medicine, Tokyo, Japan. Electronic address: mizumura.kenji@nihon-u.ac.jp.
  • Gon Y; Division of Respiratory Medicine, Department of Internal Medicine, Nihon University School of Medicine, Tokyo, Japan.
  • Harada N; Department of Respiratory Medicine, Faculty of Medicine and Graduate School of Medicine, Juntendo University, Tokyo, Japan.
  • Yamada S; Division of Respiratory Medicine, Department of Internal Medicine, Nihon University School of Medicine, Tokyo, Japan.
  • Fukuda A; Division of Respiratory Medicine, Department of Internal Medicine, Nihon University School of Medicine, Tokyo, Japan.
  • Ozoe R; Division of Respiratory Medicine, Department of Internal Medicine, Nihon University School of Medicine, Tokyo, Japan.
  • Maruoka S; Division of Respiratory Medicine, Department of Internal Medicine, Nihon University School of Medicine, Tokyo, Japan.
  • Abe S; Department of Respiratory Medicine, Faculty of Medicine and Graduate School of Medicine, Juntendo University, Tokyo, Japan.
  • Takahashi K; Department of Respiratory Medicine, Faculty of Medicine and Graduate School of Medicine, Juntendo University, Tokyo, Japan.
  • Tanaka A; Division of Respiratory Medicine and Allergology, Department of Medicine, School of Medicine, Showa University, Tokyo, Japan.
  • Sagara H; Division of Respiratory Medicine and Allergology, Department of Medicine, School of Medicine, Showa University, Tokyo, Japan.
  • Akamatsu T; Department of Respiratory Medicine, Shizuoka General Hospital, Shizuoka, Japan.
  • Shirai T; Department of Respiratory Medicine, Shizuoka General Hospital, Shizuoka, Japan.
  • Masaki K; Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.
  • Fukunaga K; Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.
  • Kobayashi K; Division of Respiratory Medicine and Allergology, Department of Medicine, Teikyo University School of Medicine, Tokyo, Japan.
  • Nagase H; Division of Respiratory Medicine and Allergology, Department of Medicine, Teikyo University School of Medicine, Tokyo, Japan.
  • Miyahara N; Department of Medical Technology, Okayama University Academic Field of Health Sciences, Okayama, Japan.
  • Kanehiro A; Social Medical Corporation Foundation of St. Francis Himeji St. Mary's Hospital, Hyogo, Japan.
  • Kitamura N; Jinyu Clinic, Tokyo, Japan.
  • Sugihara N; Jinyu Clinic, Tokyo, Japan.
  • Kumasawa F; Division of Respiratory Medicine, Department of Internal Medicine, Nihon University School of Medicine, Tokyo, Japan; Division of Respiratory Medicine, Akabane Central General Hospital, Tokyo, Japan.
  • Terada-Hirashima J; Department of Respiratory Medicine, National Center for Global Health and Medicine, Tokyo, Japan.
  • Hojo M; Department of Respiratory Medicine, National Center for Global Health and Medicine, Tokyo, Japan.
  • Chibana K; Department of Pulmonary Medicine and Clinical Immunology, Dokkyo Medical University School of Medicine, Tochigi, Japan.
  • Tagaya E; Department of Respiratory Medicine, Tokyo Women's Medical University, Tokyo, Japan.
Allergol Int ; 2024 Sep 13.
Article en En | MEDLINE | ID: mdl-39277433
ABSTRACT

BACKGROUND:

The therapeutic effectiveness of dupilumab for severe asthma in real-world settings is yet to be prospectively investigated across multiple institutions, and uncertainties persist regarding predictive factors for its effectiveness. We aimed to assess the effectiveness of dupilumab and identify predictors of its effectiveness in real-world settings using two type-2 biomarkers FeNO concentration and blood eosinophil count.

METHODS:

This prospective multicenter study included 103 patients with severe asthma. Exacerbations and respiratory functions were monitored for 24 weeks. Asthma control was evaluated using the Asthma Control Questionnaire-5. Clinical symptoms and their impact on cough and sputum were assessed using the Cough and Sputum Assessment Questionnaire (CASA-Q). Subgroup analyses of type-2 biomarkers were conducted based on FeNO levels and blood eosinophil counts at baseline.

RESULTS:

Treatment with dupilumab led to a reduction in exacerbations and enhancement in asthma control, FEV1, and CASA-Q scores. FEV1 improvement was correlated with enhancement in the sputum domain of the CASA-Q. Patients exhibiting elevated FeNO levels and blood eosinophil counts demonstrated more significant enhancements in FEV1. CASA-Q sputum domain scores were significantly higher in the group with elevated eosinophil counts. Regression analysis revealed that FeNO levels and blood eosinophil counts are significant predictors of FEV1 improvement, with blood eosinophil counts also predicting sputum improvement in patients treated with dupilumab.

CONCLUSIONS:

Type-2 biomarkers may act as indicators of improvement in FEV1 and sputum outcomes among patients with severe asthma undergoing dupilumab treatment in real-world settings.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Allergol Int Asunto de la revista: ALERGIA E IMUNOLOGIA Año: 2024 Tipo del documento: Article Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Allergol Int Asunto de la revista: ALERGIA E IMUNOLOGIA Año: 2024 Tipo del documento: Article Pais de publicación: Reino Unido